Ulcerative Colitis News and Research RSS Feed - Ulcerative Colitis News and Research

Ulcerative colitis is a common inflammatory disease of the colon characterized by inflammation and ulceration of the large bowel and rectum. The condition impairs the ability of the large bowel to absorb water which results in diarrhea, the main symptom of the condition.

Ulcerative colitis is a relapsing and remitting condition, meaning symptoms can die down for long periods but then flare-up from time to time. These flare-ups can be sudden and severe. During a period of relapse, symptoms may include bloody diarrhea, abdominal pain and a sudden urge to defecate. Other symptoms include wind, loss of appetite, weight loss, fever and fatigue.

Currently, there is no cure for the condition apart from surgery. However, certain treatments such as corticosteroids or immunosuppressants may be used to ease symptoms by reducing inflammation. Surgery for severe ulcerative colitis that does not respond to treatment involves completely removing the large bowel and re-routing the small bowel so that waste can still be expelled. This procedure is called a colectomy.

In the UK, the incidence of ulcerative colitis is around 1 in 500 and the condition is equally common among males and females. Symptoms can develop at any age, but onset usually occurs between 15 and 30 years of age.
Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

Theresa Alenghat receives 2015 AGA-CCFA-Janssen Research Award in IBD Epigenetics Research

The American Gastroenterological Association, in partnership with the Crohn's & Colitis Foundation of America and Janssen Biotech, Inc., announced today that Theresa Alenghat, VMD, PhD, from Cincinnati Children's Hospital Medical Center, OH, was awarded with the 2015 AGA-CCFA-Janssen Research Award in Inflammatory Bowel Disease (IBD) Epigenetics Research. [More]
Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Study of genetic risk factors of IBD in African-Americans published in Gastroenterology journal

Researchers at the Johns Hopkins University School of Medicine, along with colleagues at Emory University and Cedars-Sinai, have published in the journal Gastroenterology the first major, in-depth analysis of genetic risk factors of inflammatory bowel disease in African-Americans. [More]
Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). [More]
Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics launches observational clinical study in patients who survived PML

Inhibikase Therapeutics, Inc. announces the launch of an observational clinical study in patients who contracted Progressive Multifocal Leukoencephalopathy (PML), the rare and often fatal brain infection that arises as an unintended side effect of some medications used for treatment of Multiple Sclerosis, Crohn's disease, Ulcerative Colitis and certain cancers of the blood and lymph. [More]

Adults exposed to childhood physical or sexual abuse at risk for ulcerative colitis

Adults who were exposed to childhood physical or sexual abuse were approximately twice as likely to have ulcerative colitis, according to a new nationally representative study from four researchers at the University of Toronto. [More]
Study uncovers role of intra-abdominal fat cells in development and progression of IBD

Study uncovers role of intra-abdominal fat cells in development and progression of IBD

Intra-abdominal fat cells may contribute to the development and progression of inflammatory bowel disease (IBD), according to a study published in Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association. [More]
People with IBD experience higher anxiety risk compared to peers without IBD

People with IBD experience higher anxiety risk compared to peers without IBD

People who have inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, have twice the odds of having a generalized anxiety disorder at some point in their lives when compared to peers without IBD, according to a new study published by University of Toronto researchers. [More]
Consumption of B-GOS prebiotic has positive effect on gut microbiota, immune systems of elderly people

Consumption of B-GOS prebiotic has positive effect on gut microbiota, immune systems of elderly people

Clasado Biosciences Limited, the producers and suppliers of the second generation prebiotic Bimuno, a unique trans-galactooligosaccharide, and the Department of Food and Nutritional Sciences, The University of Reading, UK, today announce the results of human research demonstrating the positive effects of an advanced prebiotic on the immune system of the elderly. [More]
Twenty Radboud researchers receive Veni grant as part of Innovational Research Incentives Scheme

Twenty Radboud researchers receive Veni grant as part of Innovational Research Incentives Scheme

Twenty young and promising researchers from Nijmegen - eleven from Radboud University and nine from Radboudumc - are each to receive up to 250,000. NWO (The Netherlands Organisation for Scientific Research) is awarding the Veni grant as part of the Innovational Research Incentives Scheme. [More]
Groundbreaking experimental therapy has ability to suppress ulcerative colitis

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information. [More]
Study shows regions of genome underlying IBD consistent around the world

Study shows regions of genome underlying IBD consistent around the world

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted under the auspices of the International IBD Genetics Consortium, included nearly 10,000 DNA samples from people of East Asian, Indian or Iranian descent and an existing set of 86,640 samples drawn from across Europe, North America and Oceania. [More]
Biosimilars show promise for children with IBD, but more research needed

Biosimilars show promise for children with IBD, but more research needed

Children with inflammatory bowel disease (IBD) who are doing well on specific biological medications should not be switched to recently approved "biosimilar" products, concludes an expert consensus statement of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. [More]
Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma to purchase global rights for AstraZeneca’s Entocort excluding the U.S.

Tillotts Pharma AG, part of the Zeria Group, announced today that it has entered into an agreement for the acquisition of the global rights for Entocort (budesonide) from AstraZeneca, excluding the U.S., which will remain with AstraZeneca. [More]
Scientists detail how stereomicroscopy can help in assessing issues within gastrointestinal tract

Scientists detail how stereomicroscopy can help in assessing issues within gastrointestinal tract

A technology whose roots date to the 1800s has the potential to offer an extraordinary new advantage to modern-day medicine. [More]
Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents. [More]
Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies show that fecal transplantation may help fight against ulcerative colitis

Two new studies led by researchers from the Farncombe Family Digestive Health Research Institute at McMaster University show that transplantation of fecal matter may be a useful tool in the fight against ulcerative colitis (UC). [More]
ExeGi Pharma granted product license to sell Visbiome formulation in Canada

ExeGi Pharma granted product license to sell Visbiome formulation in Canada

ExeGi Pharma, a company focused on developing and commercializing live biotherapeutics and probiotic treatments, announced today that it has been granted a product license by the Health Canada Natural and Non-prescription Health Products Directorate (NNHPD) to sell Visbiome in Canada. [More]
Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms. [More]
Study opens up new line of research into origin of digestive diseases

Study opens up new line of research into origin of digestive diseases

There are numerous studies related to the absorption of nutrients from the stomach since understanding what happens in our digestive system is crucial, for example, in order to be able to avoid in the future some of the diseases that affect part of the population to a lesser or greater extent. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
Advertisement